Cover Image
市場調查報告書

慢性脫髓鞘多發性神經炎 (CIDP) :開發中產品分析

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 328617
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
慢性脫髓鞘多發性神經炎 (CIDP) :開發中產品分析 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 58 Pages
簡介

慢性脫髓鞘多發性神經炎 (CIDP)是造成惡化型四肢肌肉無力及感覺障礙的神經疾病。這個疾病是由於末梢神經的髓磷脂鞘損壞所引起。會出現四肢中心及末端部位的衰弱(初期症狀),站起時暈眩、手腳疼痛、麻痺等症狀。

本報告提供全球治療慢性脫髓鞘多發性神經炎 (CIDP) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

慢性脫髓鞘多發性神經炎 (CIDP) 概要

治療藥的開發

  • 開發中產品的概要

慢性脫髓鞘多發性神經炎 (CIDP) :企業開發中的治療藥

慢性脫髓鞘多發性神經炎 (CIDP) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

慢性脫髓鞘多發性神經炎 (CIDP) :企業開發中的產品

慢性脫髓鞘多發性神經炎 (CIDP) 的治療藥的開發企業

  • Baxalta Incorporated
  • CSL Limited
  • GeNeuro SA
  • 田邊三菱製藥
  • Pfizer Inc.
  • TEIJIN FIBERS製藥
  • 慢性脫髓鞘多發性神經炎 (CIDP) :治療藥的評估
  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • GL-2045
  • GNbAC-1
  • immune globulin (human)
  • immune globulin (human)
  • immune globulin (human)

慢性脫髓鞘多發性神經炎 (CIDP) :最近的開發平台趨勢

慢性脫髓鞘多發性神經炎 (CIDP) :暫停中的計劃

慢性脫髓鞘多發性神經炎 (CIDP) :產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8381IDB

Summary

Global Markets Direct's, 'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016', provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • The report reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics under Development by Companies
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Products under Development by Companies
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
    • CSL Limited
    • GeNeuro SA
    • Mitsubishi Tanabe Pharma Corporation
    • Octapharma AG
    • Pfizer Inc.
    • Shire Plc
    • Teijin Pharma Limited
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (hyaluronidase (human) (recombinant) + immune globulin (human)) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fingolimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GL-2045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNbAC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
      • Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy
      • Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen
      • Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
      • May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy
      • Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by CSL Limited, H2 2016
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H2 2016
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H2 2016
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc., H2 2016
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Shire Plc, H2 2016
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top